Adopting a new strategy in food allergies and others, South San Francisco-based Iggenix Inc. launched with a $10 million series A round to fund work that CEO Bruce Hironaka told BioWorld puts the company “at the front of the wave.” Companies in the allergy space generally “have not taken full advantages of the developments that we’ve seen in the biotech industry over the last 20 or 30 years,” he said.
Mantra Bio Inc., of San Francisco, plans to take its new $25 million series A financing and advance its pipeline and partnering efforts for engineering targeted exosome vehicles. The company platform integrates computational approaches, wet biology and robotics to leverage exosome diversity and enable rational design of therapeutics for a range of tissue and cellular targets.
Nura Bio Inc., a company working to discover and develop new neuroprotective medicines, has closed a $73 million series A financing that President and CEO Alpna Seth said would help her team advance a multitarget pipeline, initially led by an inhibitor of the sterile alpha TIR motif protein 1 inhibitor (SARM1).
DUBLIN – Versant Ventures is committing $35 million in series A funding to Bright Peak Therapeutics Inc., which is developing a pipeline of engineered cytokines that are produced using a novel chemical synthesis technique rather than the recombinant methods that have underpinned more than four decades of biotechnology development.
LONDON – Enthera Pharmaceuticals Srl has announced the largest international series A to date for an Italian biotech, closing a €28 million (US$32.9 million) round, to take programs in type 1 diabetes and inflammatory bowel disease (IBD) into phase I development.
LONDON - The combined force of Belgian life sciences has been brought together in the launch of Exevir Bio BV, which arrives on the scene with a €23 million (US$27 million) series A and ready for a phase I study of its novel antiviral therapy in hospitalized COVID-19 patients.
As Carmel, Ind.-based MBX Biosciences Inc., taking aim at rare endocrine diseases, disclosed $34.6 million in a series A financing, CEO and co-founder Kent Hawryluk told BioWorld that “everyone on the leadership team we’ve worked with in prior lives, so to speak,” adding that he’s “excited to have the band back together.”
DUBLIN – Tubulis GmbH raised €10.7 million (US$12.3 million) in a series A round to progress a next-generation antibody-drug conjugate (ADC) platform, which, it claims, will improve both the stability of ADC constructs and the efficiency with which they are generated.
PERTH, Australia – With a series A investment in hand, Glyscend Therapeutics Inc. will take its polymer therapeutic that mimics the effect of gastric bypass surgery to Australia next year to begin clinical trials.
Courtesy of a $50 million series A, Adagio Therapeutics Inc. will join a raft of other companies attempting to end the COVID-19 pandemic with antibodies.
RSS
